氯吡格雷联合阿司匹林治疗急性缺血性卒中与高危短暂性脑缺血发作
该国际随机试验纳入4881例轻型缺血性卒中或高危TIA患者,比较氯吡格雷(首日负荷600 mg,随后75 mg/日)联合阿司匹林(50–325 mg/日)与单用阿司匹林(50–325 mg/日)的效果。90天主要缺血事件(缺血性卒中、心肌梗死或缺血性血管性死亡)在联合组为5.0%,单用阿司匹林组为6.5%(HR 0.75,95%CI 0.59–0.95,P=0.02),多数事件发生在初始事件后第一周。大出血在联合组为0.9%,单用阿司匹林组为0.4%(HR 2.32,95%CI 1.10–4.87,P=0.02)。试验因联合治疗同时降低缺血事件和增加出血风险而在入组84%预计例数后提前终止。
要点
- 轻型缺血性卒中或高危TIA患者,氯吡格雷联合阿司匹林较单用阿司匹林降低90天主要缺血事件风险:联合组5.0% vs 单用阿司匹林组6.5%(HR 0.75,95%CI 0.59–0.95,P=0.02)。
- 联合治疗增加90天大出血风险:联合组0.9% vs 单用阿司匹林组0.4%(HR 2.32,95%CI 1.10–4.87,P=0.02)。
- 多数主要缺血事件发生在初始事件后第一周。
- 氯吡格雷用法:首日负荷600 mg,随后75 mg/日;阿司匹林50–325 mg/日,剂量由各中心研究者选择。
- 试验在入组84%预计例数后提前终止,因数据与安全监察委员会认定联合治疗在90天时主要缺血事件风险更低但大出血风险更高。
适用人群与场景
- 轻型缺血性卒中或高危短暂性脑缺血发作(TIA)患者。
处置流程与药物剂量
- 氯吡格雷:首日负荷剂量600 mg,随后75 mg/日。
- 阿司匹林:50–325 mg/日,具体剂量由各中心研究者选择。
- 联合治疗组使用氯吡格雷加阿司匹林,对照组使用阿司匹林加安慰剂。
研究设计与关键结果
- 随机试验,纳入4881例患者,269个国际中心。
- 主要疗效终点为90天主要缺血事件(缺血性卒中、心肌梗死或缺血性血管性死亡)复合终点:氯吡格雷联合阿司匹林组121/2432例(5.0%) vs 阿司匹林加安慰剂组160/2449例(6.5%),HR 0.75(95%CI 0.59–0.95),P=0.02。
- 大出血:氯吡格雷联合阿司匹林组23例(0.9%) vs 阿司匹林加安慰剂组10例(0.4%),HR 2.32(95%CI 1.10–4.87),P=0.02。
- 多数主要缺血事件发生在初始事件后第一周。
- 试验在入组84%预计例数后提前终止,因数据与安全监察委员会认定联合治疗在90天时主要缺血事件风险更低但大出血风险更高。
证据类型、等级与局限
- 证据类型:随机对照试验(RCT)。
- 试验由美国国立神经疾病与卒中研究所资助;POINT试验,ClinicalTrials.gov注册号NCT00991029。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于轻型缺血性卒中或高危TIA患者,作者报告氯吡格雷联合阿司匹林较单用阿司匹林降低90天主要缺血事件风险,但增加大出血风险。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Combination antiplatelet therapy with clopidogrel and aspirin may reduce the rate of recurrent stroke during the first 3 months after a minor ischemic stroke or transient ischemic attack (TIA). A trial of combination antiplatelet therapy in a Chinese population has shown a reduction in the risk of recurrent stroke. We tested this combination in an international population.
METHODS: In a randomized trial, we assigned patients with minor ischemic stroke or high-risk TIA to receive either clopidogrel at a loading dose of 600 mg on day 1, followed by 75 mg per day, plus aspirin (at a dose of 50 to 325 mg per day) or the same range of doses of aspirin alone. The dose of aspirin in each group was selected by the site investigator. The primary efficacy outcome in a time-to-event analysis was the risk of a composite of major ischemic events, which was defined as ischemic stroke, myocardial infarction, or death from an ischemic vascular event, at 90 days.
RESULTS: A total of 4881 patients were enrolled at 269 international sites. The trial was halted after 84% of the anticipated number of patients had been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days. Major ischemic events occurred in 121 of 2432 patients (5.0%) receiving clopidogrel plus aspirin and in 160 of 2449 patients (6.5%) receiving aspirin plus placebo (hazard ratio, 0.75; 95% confidence interval [CI], 0.59 to 0.95; P=0.02), with most events occurring during the first week after the initial event. Major hemorrhage occurred in 23 patients (0.9%) receiving clopidogrel plus aspirin and in 10 patients (0.4%) receiving aspirin plus placebo (hazard ratio, 2.32; 95% CI, 1.10 to 4.87; P=0.02).
CONCLUSIONS: In patients with minor ischemic stroke or high-risk TIA, those who received a combination of clopidogrel and aspirin had a lower risk of major ischemic events but a higher risk of major hemorrhage at 90 days than those who received aspirin alone. (Funded by the National Institute of Neurological Disorders and Stroke; POINT ClinicalTrials.gov number, NCT00991029 .).
参考来源
- Johnston SC, Easton JD, Farrant M, et al. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med. 2018. PMID: 29766750. doi:10.1056/NEJMoa1800410
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。